Overview

An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma

Status:
Terminated

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy (effectiveness) and tolerability (how well a participant can stand a particular medicine or treatment; ability to be used) of bortezomib in combination with rituximab standard therapy (medicine or medical care given to a participant for a disease or condition) in participants with relapsed or refractory (not responding to treatment) follicular lymphoma (a cancer of the lymph nodes [or tissues] in follicle).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen-Cilag G.m.b.H

Treatments:

Bortezomib
Rituximab